Helix Acquisition CORP Ii Form 4 insider transactions

BridgeBio Oncology Therapeutics CEO Eli M. Wallace was granted 499,731 stock options with an exercise price of $9.59.

BridgeBio Oncology Therapeutics' CFO, Uneek Mehra, was granted 633,570 stock options with an exercise price of $9.59, vesting over time.

A director and 10% owner of BridgeBio Oncology Therapeutics, Inc. reported significant share acquisitions and forfeitures related to the recent business combination.

Nebojsa Obradovic has ceased to be the Chief Legal Officer of BridgeBio Oncology Therapeutics, Inc., effective August 11, 2025.

Caleb Tripp has filed a voluntary exit report, confirming his departure as Chief Financial Officer of BridgeBio Oncology Therapeutics, Inc. effective August 11, 2025.

A former director of Helix Acquisition Corp. II reported the conversion of 30,000 shares into common stock of BridgeBio Oncology Therapeutics, Inc. following a business combination and domestication.

A former director of Helix Acquisition Corp. II converted 30,000 shares into BridgeBio Oncology Therapeutics common stock following a business combination and domestication.

A former director of Helix Acquisition Corp. II converted 30,000 Class B ordinary shares into common stock of BridgeBio Oncology Therapeutics, Inc. following a business combination and domestication.

Helix Acquisition Corp. II shareholders overwhelmingly approved all proposals for its business combination with TheRas, Inc. (d/b/a BridgeBio Oncology Therapeutics), clearing the path for the merger and domestication.

Clinical-stage biopharmaceutical company BBOT announced the appointment of Uneek Mehra, a seasoned financial executive with over 28 years of global experience, as its new Chief Financial Officer, coinciding with the progression of its business combination with Helix Acquisition Corp. II.

Helix Acquisition Corp. II and BridgeBio Oncology Therapeutics announced that the SEC has declared their Form S-4 registration statement effective, paving the way for a shareholder vote on their proposed business combination.

TheRas, Inc. (BridgeBio Oncology Therapeutics) and Helix Acquisition Corp. II are set to combine, with plans to file a registration statement with the SEC.

Helix Acquisition Corp. II will merge with BridgeBio Oncology Therapeutics, a clinical-stage biopharmaceutical company, to advance novel small molecule therapeutics targeting RAS and PI3Ka malignancies.

BridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II (HLXB) have announced a definitive business combination agreement to create a publicly listed biotechnology company focused on advancing RAS and PI3K-targeting medicines.

Helix Holdings II LLC reports the transfer of 30,000 Class B Ordinary Shares to Albert A. Holman, III, in connection with his appointment as a director of Helix Acquisition Corp. II.

Bihua Chen, CEO and Chairperson of Helix Acquisition Corp. II, reports the transfer of 30,000 Class B Ordinary Shares from the Sponsor to Albert A. Holman, III, in connection with his appointment as a director.